(±)7(8)-EpDPA
![]() |
- $41 - $642
- Product name: (±)7(8)-EpDPA
- CAS: 895127-66-9
- MF: C22H32O3
- MW: 344.49
- EINECS:
- MDL Number:
- Synonyms:(±)7(8)-EpDPA;7(8)-Epoxy-Docosapentaenoic acid;(4Z)-6-[3-(2(Z),5(Z),8(Z),11Z)-2,5,8,11-tetradecatetraen-1-yl-2-oxiranyl]-4-hexenoic acid;4-Hexenoic acid, 6-[3-(2Z,5Z,8Z,11Z)-2,5,8,11-tetradecatetraen-1-yl-2-oxiranyl]-, (4Z)-;7(8)-Epoxy-DPA;()7(8)-EpDPA(solution in ethanol)
4 prices
Selected condition:
Brand
- Cayman Chemical
Package
- 25μg
- 50μg
- 100μg
- 500μg
- ManufacturerCayman Chemical
- Product number10465
- Product description(±)7(8)-EpDPA ≥95%
- Packaging25μg
- Price$41
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number10465
- Product description(±)7(8)-EpDPA ≥95%
- Packaging50μg
- Price$78
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number10465
- Product description(±)7(8)-EpDPA ≥95%
- Packaging100μg
- Price$145
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number10465
- Product description(±)7(8)-EpDPA ≥95%
- Packaging500μg
- Price$642
- Updated2024-03-01
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Cayman Chemical | 10465 | (±)7(8)-EpDPA ≥95% | 25μg | $41 | 2024-03-01 | Buy |
Cayman Chemical | 10465 | (±)7(8)-EpDPA ≥95% | 50μg | $78 | 2024-03-01 | Buy |
Cayman Chemical | 10465 | (±)7(8)-EpDPA ≥95% | 100μg | $145 | 2024-03-01 | Buy |
Cayman Chemical | 10465 | (±)7(8)-EpDPA ≥95% | 500μg | $642 | 2024-03-01 | Buy |
Properties
Boiling point :486.9±40.0 °C(Predicted)
Density :0.994±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml
pka :4.58±0.10(Predicted)
Density :0.994±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml
pka :4.58±0.10(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|